Julia Conley, staff writer
"A big win for solidarity with all people on the move...and against the criminalization of helpers."
Jessica Corbett, staff writer
"It is our responsibility to ban this poison from our environment."
Jake Johnson, staff writer
"This is clearly one of those examples when legality is a matter of power, and...


Up there in the annals of multinational corporations doing heinous things in the name of obscene profits comes the German-based Bayer's response to India ending the pharma giant's monopoly for a pricey new anti-cancer drug, thus allowing a small Indian company to make a generic version that poor sick people can afford. A year of Bayer's Nexavar costs $96,000 in the U.S. and $69,000 in India, 41 times the per capita income; India's Natco Ltd. made it for $177 a year. Outraged Bayer officials...